Ifinatamab deruxtecan
Ifinatamab Deruxtecan[edit | edit source]
Ifinatamab deruxtecan is a novel antibody-drug conjugate (ADC) designed for the targeted treatment of certain types of cancer. It combines a monoclonal antibody specific to a tumor-associated antigen with a potent cytotoxic agent, deruxtecan, which is a derivative of the chemotherapy drug exatecan.
Mechanism of Action[edit | edit source]
Ifinatamab deruxtecan works by specifically targeting cancer cells that express a particular antigen. The monoclonal antibody component of the ADC binds to the antigen on the surface of the cancer cell. Once bound, the entire ADC is internalized into the cell, where the cytotoxic agent, deruxtecan, is released. This release occurs through the cleavage of a linker that connects the antibody to the drug. The released deruxtecan then exerts its cytotoxic effects by inhibiting topoisomerase I, leading to DNA damage and ultimately cell death.
Development and Clinical Trials[edit | edit source]
Ifinatamab deruxtecan is currently under investigation in various clinical trials to evaluate its efficacy and safety in treating different types of cancer, including breast cancer, lung cancer, and gastric cancer. These trials aim to determine the optimal dosing, therapeutic efficacy, and potential side effects of the drug.
Potential Side Effects[edit | edit source]
As with other ADCs, ifinatamab deruxtecan may cause a range of side effects. Common side effects include nausea, fatigue, and myelosuppression. More serious side effects can include interstitial lung disease and severe neutropenia. Monitoring and management of these side effects are crucial during treatment.
Future Directions[edit | edit source]
Research is ongoing to explore the full potential of ifinatamab deruxtecan in combination with other therapies, such as immunotherapy and radiotherapy. Additionally, efforts are being made to identify biomarkers that can predict response to treatment, which would allow for more personalized therapy approaches.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
